ArticleRespiratory research2024
The prevalence and mortality risks of PRISm and COPD in the United States from NHANES 2007-2012.
Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Estimation of mortality hazard ratios by COPD grade using a systematic review and network meta-analysis: deriving grade-, sex-, and age-specific mortality for a German COPD decision model.Scientific reports · 2026Pooled it
- The Burden of Chronic Obstructive Pulmonary Disease in the US: A Systematic Review of Nationally Representative Health Surveys.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- All-Cause and Cause-Specific Mortality in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Diagnostic outcomes of the 2023 race-neutral and 2012 race-specific global lung function initiative spirometry equations in healthy Algerian adults: a cross-sectional comparative analysis.The Libyan journal of medicine · 2026Article
- Mechanisms of dyspnoea and exercise intolerance in smokers with preserved ratio impaired spirometry.European journal of applied physiology · 2026Article
- Respiratory health impacts of coal-fired power plant emissions with transboundary environmental complexities.Scientific reports · 2026Article
- Vapors, gases, dusts and fumes at work and chronic obstructive pulmonary disease/bronchitis: a systematic review and meta-analyses.Journal of occupational medicine and toxicology (London, England) · 2026Article
- Prevalence of PRISm and COPD and associated factors in a university medical centre spirometry unit: a cross-sectional analysis.BMJ open · 2026Article
- Preserved Ratio Impaired Spirometry in the Ugandan Link Cohort: A Longitudinal Follow-Up.CHEST pulmonary · 2026Article
- Preserved Ratio Impaired Spirometry in Low- and Middle-Income Countries: An Emerging Cardiopulmonary Phenotype and Cardiovascular Risk-A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Association between steatotic liver disease (MASLD, met-ALD, and ALD) with preserved ratio impaired spirometry: a population-based study.BMC pulmonary medicine · 2026Article
- E-cigarette Duration and Incident COPD Among Adults Aged 40 Years and Older with a Smoking History.medRxiv : the preprint server for health sciences · 2026Article
- Integrating Preoperative Preserved Ratio Impaired Spirometry and Inflammatory Markers to Predict Postoperative Complications and Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy.Journal of inflammation research · 2026Article
- Rectifying COPD management: a critical analysis of the Global Initiative for Chronic Obstructive Lung Disease strategy.ERJ open research · 2026Review
- Risk prediction for acute kidney disease and adverse outcomes in patients with chronic obstructive pulmonary disease: an interpretable machine learning approach.Renal failure · 2025Article
- The joint association between inflammation and centripedal obesity with mortality risk in patients with preserved ratio impaired spirometry.NPJ primary care respiratory medicine · 2025Article
- Association between preserved ratio impaired spirometry and cardiovascular disease subtypes: evidence from NHANES 2007-2012.BMC cardiovascular disorders · 2025Article
- Association between visceral lipid accumulation indicator and preserved ratio impaired spirometry in US adults: a population-based study from 2007 to 2012.Lipids in health and disease · 2025Article
- A comprehensive investigation of the relationship between dietary fatty acid intake and preserved ratio impaired spirometry: multimethodology based on NHANES.Lipids in health and disease · 2025Article
- Association between preserved ratio impaired spirometry and frailty risk among US adults: a cross-sectional study.BMJ open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWe estimated the prevalence and mortality risks of preserved ratio impaired spirometry (PRISm) and chronic obstructive pulmonary disease (COPD) in the US adult population.
methodsWe linked three waves of pre-bronchodilator spirometry data from the US National Health and Nutritional Examination Survey (2007-2012) with the National Death Index. The analytic sample included adults ages 20 to 79 without missing data on age, sex, height, BMI, race/ethnicity, and smoking status. We defined COPD (GOLD 1, 2, and 3-4) and PRISm using FEV
resultsPrevalence of COPD and PRISm from 2007-2012 ranged from 13.1%-14.3% and 9.6%-10.2%, respectively. We found significant differences in prevalence by sex, age, smoking status, and race/ethnicity. Males had higher rates of COPD regardless of stage, while females had higher rates of PRISm. COPD prevalence increased with age, but not PRISm, which was highest among middle-aged individuals. Compared to current and never smokers, former smokers showed lower rates of PRISm but higher rates of GOLD 1. COPD prevalence was highest among non-Hispanic White individuals, and PRISm was notably higher among non-Hispanic Black individuals (range 31.4%-37.4%). We found associations between PRISm and all-cause mortality (hazard ratio [HR]: 2.3 95% CI: 1.9-2.9) and various cause-specific deaths (HR ranges: 2.0-5.3). We also found associations between GOLD 2 (HR: 2.1, 95% CI: 1.7-2.6) or higher (HR: 4.2, 95% CI: 2.7-6.5) and all-cause mortality. Cause-specific mortality risk varied within COPD stages but typically increased with higher GOLD stage.
conclusionsThe prevalence of COPD and PRISm remained stable from 2007-2012. Greater attention should be paid to the potential impacts of PRISm due to its higher prevalence in minority groups and its associations with mortality across various causes including cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.